+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Alzheimer'S Disease: Pharmacuetical Drugs Vs. Medicinal Plants - Markets, Competitors and Opportunities: 2015-2020 Analysis and Forecasts

  • ID: 3292766
  • Report
  • Region: Global
  • 77 Pages
  • Amadee & Company, Inc
1 of 4


  • AbbVie
  • Biogen
  • Eli Lilly
  • Johnson & Johnson
  • Merck
  • Pfizer
  • MORE
The objective of this report is to provide a detailed analysis of Alzheimer’s disease (AD) and the pharmaceutical drugs and medicinal plants used to treat and prevent it. It also provides an overview of the leading companies serving this market and their current and future product offerings.

This report will prove useful for people dealing with Alzheimer’s disease, trying to prevent it, doing R&D on new drugs for it, or investing in this industry.

The conclusion of this report is that the future hope for treating and preventing Alzheimer’s disease lies in medicinal plants.

Alzheimer’s disease has become a major, public health problem. Globally, approximately 56 million people are estimated to be Alzheimer’s sufferers in 2015. An estimated 5.6 million Americans now have Alzheimer’s and, by mid-century, fueled in large part by the baby boom generation, the number of people living with AD in the United States is projected to reach 13.8 million.

At the moment, unfortunately, there is no cure available to impede the severe-type of AD, and only symptomatic treatment is applicable for the moderate and mild-types, which often lasts about 2-3 years.

Modern treatment strategies typically comprise of anticholinesterases, antioxidants, alpha and beta-secretase inhibitors, and N-methyl-D-aspartate (NMDA) receptor antagonists. But none of the current AD pharmaceutical drugs has demonstrated a disease modifying effect or is very efficacious at slowing progression. And next-generation treatments capable of slowing the disease progression will not reach the market for 3-5 years.

Further exacerbating the problem, the pharmaceutical industry is facing serious challenges as the drug discovery process for neurodegenerative diseases is becoming extremely expensive, riskier and critically inefficient. Also, a significant shift from a single-target to a multi-target drug approach, especially for chronic and complex disease syndromes, is taking place.

Because of the complexity of chemical content (in terms of both diverse classes and multiple analogues within any class) and variety of bioactivities, medicinal plants offer the prospect of the kind of built in poly-pharmacology that is increasingly apparent for orthodox drugs.

Also, medicinal plants can serve as chemopreventive agents, which induce therapeutic outcomes that modulate the aggregation process of beta-amyloid, and provide measureable cognitive benefits in the aging process. As a result, medicinal plants may be particularly relevant to long-term, potentially prophylactic use against AD by providing neuroprotection.

This report provides an estimate of global Alzheimer’s disease pharmaceutical drug production, as well as estimates for several medical plants production that are useful in treating and preventing AD. A detailed analysis of current and future drug offerings is given, along with the companies producing and doing R&D on them. Additionally, a detailed analysis of medicinal plants that have been clinically evaluated for treating and preventing Alzheimer’s disease is provided.
Note: Product cover images may vary from those shown
2 of 4


  • AbbVie
  • Biogen
  • Eli Lilly
  • Johnson & Johnson
  • Merck
  • Pfizer
  • MORE
1. Executive Summary

2. Introduction
- Report Objectives
- Methodology and Sources
- Statistical Notes

3. Alzheimers Disease
- Alzheimer’s Disease Overview
- Cholinergic Hypothesis
- New Drugs 2-3 Years Away
- Alzheimer’s Severity Measures
- Amyloid Hypothesis
- How Anti-Amyloid Beta Antibodies Work
- Basic Science Supports Amyloid Hypothesis
- If The Amyloid Hypothesis Is Wrong
- Next-Generation Treatments Focused On Beta-Amyloid
- Anti-Aß Therapies In Development
- Bapineuzumab
- Solanezumab
- BIIB037
- Crenezumab
- Gantenerumab
- BAN2401
- Other Alzheimer’s Therapies in Development
- Tau And Neurofibrillary Tangles
- Safety Risks
- Acetylcholinesterase Inhibitors Are The Standard Of Care
- New Alzheimer’s Drug Development Guidelines
- New Diagnostics Will Expand The Market
- Existing Treatments Have Significant Limitations
- Next-Generation Treatments Far Away

4. Medicinal Plants And Alzheimer’S Disease
- Background
- Healthy Brain Aging
- Pharmaceutical Approach Is Not Working
- Phytochemical Approach
- Plant Extracts and Compounds Have Been Extensively Reviewed
- Cognitive Function
- Natural Products Derived From European Plants
- Galantamine
- Sage
- Lemon Balm
- Periwinkle
- Natural Products Derived from Traditional Chinese Medicines
- Ginkgo
- Ginseng
- Huperzine
- Other Traditional Chinese and Japanese Herbal Medicines
- Behavioral and Psychological Symptoms
- Behavioral and Psychological Symptoms of Dementia
- BPSD as a Whole
- Agitation
- Alzheimer’s Disease Prevention/Stabilization
- Conclusions

5. Alzheimers Disease Drugs Market
- Alzheimer’s Disease Is Now A Pandemic
- Worldwide Prevalence of Alzheimer’s Disease
- Global Market for Alzheimer's Disease Remedies
- U.S. Alzheimer's Disease Sufferers And Treatment Metrics
- Medications Are First Line of Defense
- Global Market For Alzheimer’s Drugs
- Major Trends and Issues
- Producer Market Shares
- Aricept In Decline
- Namenda Mainstay Symptomatic Therapy
- Exelon Patch
- Razadyne Destroyed By Generics
- BACE Inhibitors In Clinical Trials
- Gamma-Secretase Modulators
- CAD106 Targets Mild AD Patients
- Low Expectations For Rember
- Davunetide Targets Tau/Microtubule Dynamics
- Dietary Supplement Axona
- PBT2 Fails To Meet Primary Endpoint
- Nypta Offers A New Approach
- New Therapeutic Approaches In The Next Decade
- Bexarotene
- Death Receptor 6
- Gamma-Secretase Activating Protein
- O-Linked N-Acetylglucosaminidase
- Statins Not A Viable Therapy
- NSAIDs Fall Short
- Long-Term Outlook for Alzheimer’s Disease Drugs

1.) Clinical Endpoints Used In Alzheimer’s Disease Clinical Trials
2.) Comparison Of Alzheimer’s Drugs In Development
3.) Alzheimer’s Disease Diagnostics In Development
4.) Symptomatic Drugs For The Treatment Of Alzheimer’s Disease
5.) European Plants And Their Constituents With Relevance For Dementia: Cognition
6.) Plants Used In Traditional Chinese Medicine And Their Constituents With Relevance For Dementia: Cognition
7.) Plants And Their Constituents With Relevance For Dementia: Behavioral And Psychological Symptoms
8.) Plants And Their Constituents With Relevance For Dementia: Disease Prevention
9.) Number of Alzheimer’s Sufferers by Region (Million): 2015
10.) Alzheimer’s Disease Drug Production Compared to Nutraceuticals, Marijuana, TCM, Green Tea and Turmeric Production ($ Million): 2015-2020
11.) U.S. Alzheimer's Disease Sufferers And Treatments Metrics (Million)
12.) Global Alzheimer's Disease Drug Sales ($ Billion): 2015-2020
13.) Alzheimer's Disease Drug Production By Type ($ Million): 2014-2020
14.) Alzheimer's Drugs Producers Sales and Market Shares ($ Million): 2013-2019
15.) Alzheimer’s Disease Drugs R&D Pipeline by Product And Company
16.) Next Generation Alzheimer’s Disease Drugs Market (Billion Yen): 2025-2035

1.) Targeting Of Beta-Amyloid In The Treatment Of Alzheimer’s Disease
2.) Global Trajectory of Dementia Patients (Million): 2013-2050
Note: Product cover images may vary from those shown
3 of 4


4 of 4
- AbbVie
- AstraZeneca
- Biogen
- Eisai
- Eli Lilly
- Johnson & Johnson
- Lundbeck
- Merck
- Novartis
- Pfizer
- Roche
- TauRx

Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/3292766